AA
TARA icon

ALPS Advisors’s Protara Therapeutics TARA Stock Holding History

ALPS Advisors’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$229K Buy
44,029
+1,640
+4% +$9.71K ﹤0.01% 988
2025
Q4 		$226K Buy
+42,389
New +$236K ﹤0.01% 965
2021
Q2 		– Sell
-20,279
Closed -$319K – 917
2021
Q1 		$319K Buy
20,279
+209
+1% +$3.88K ﹤0.01% 782
2020
Q4 		$486K Buy
+20,070
New +$433K 0.01% 502

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

ALPS Advisors's TARA Position: Q1 2026 in Review

ALPS Advisors increased its Protara Therapeutics (TARA) stake by 3.9% in Q1 2026, buying an estimated $9.71K and bringing the position to 44,029 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #988.

ALPS Advisors first reported a position in TARA in Q4 2020 and has held it in 4 quarters since. The position peaked at $486K in Q4 2020. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • ALPS Advisors held 44,029 shares of Protara Therapeutics worth $229K as of Q1 2026.
  • ALPS Advisors bought 1,640 Protara Therapeutics shares in Q1 2026, an estimated $9.71K.
  • Protara Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q1 2026, its #988 holding.
  • ALPS Advisors first reported a position in Protara Therapeutics in Q4 2020 and has held it in 4 quarters since.
  • ALPS Advisors's Protara Therapeutics position peaked at $486K in Q4 2020.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.